Mirion Technologies, Inc. (MIR) Earnings Call Transcript & Summary
July 29, 2026
Earnings Call Speaker Segments
Eric Linn
executiveThanks, Liz, and hello everybody on this call. It's great to have you with us for Mirion's earnings discussion covering the second quarter of 2026. Here with me today are Tom Logan, who founded Mirion and serves as Chairman and CEO, along with Brian Schopfer, our CFO and President of the Medical Group. Ahead of our prepared comments, I'd like to note that anything we say on this call contains forward-looking statements, and outcomes in reality could vary significantly from what those statements anticipate. You can read about the elements that might lead to different outcomes in our 10-K annual reports, our 10-Q quarterly reports, and other documents Mirion files with the SEC, specifically in the Risk Factors section. When we reference quarters in what follows, we mean the quarter that closed on June 30, 2026, unless we say otherwise. Some of the financial metrics we'll discuss today fall outside generally accepted accounting principles. You can find a reconciliation between those non-GAAP metrics and their nearest GAAP counterparts in the appendix of the presentation that goes with this call. Everything related to earnings is available on the Investor Relations page of our site, www.mirion.com. With all that said, I'll hand things over to Tom, who's starting on Panel 3.
Tom Logan
executiveEric, thanks, and hello everyone who's with us on today's call. After the market shut down yesterday, we put out our results for the second quarter. Yet again, we showed orders and backlog on the rise, and that included wins on some key large opportunities. Growth in orders at a double-digit pace is driving further backlog growth as momentum in nuclear power keeps gaining traction. We also showed adjusted EBITDA margins expanding across both operating segments and for the whole enterprise. Improved mix and pricing more than made up for dilution from M&A and wider inflationary pressures. All of this sets us up for a strong acceleration in the back half of 2026; we're keeping our 2026 full year guidance as is, which points to a meaningful lift in financial performance over the rest of the year. Brian will take you through the specifics, including what we expect for the third quarter and for the second half. Our view remains that momentum behind nuclear power keeps building. That's nowhere clearer than in North America itself. As I've noted on earlier calls, the nuclear super trend keeps widening, and the headlines from this quarter shown on Panel 4 make that plain as day. In the U.S., improvements in regulation and policy are bolstering momentum for nuclear power. According to the NRC, changes have been introduced that streamline the licensing process — cutting unnecessary red tape, offering clearer rules, and, crucially, not compromising on safety. On top of that, the Department of Energy is providing a $17.5 billion loan initiative to support the building of new reactors, which shows that both financing options and regulatory routes are beginning to unlock simultaneously. Beyond policy, we're encouraged by what's actually being delivered. Four advanced reactor designs achieved criticality under the DOE's Reactor Pilot Program, surpassing the program's own goal of 3 before the July 4 cutoff. That's tangible evidence that small modular reactor designs are progressing. What really matters here is that Mirion, Paragon and Certrec played a central role in each of those advanced reactor programs; meanwhile, on the demand side, new power agreements continue to be struck. Constellation and Walmart came out with a fresh nuclear power deal — a first for Walmart, and among the earliest arrangements of its kind between a large retailer and a nuclear plant in the U.S. New York State and Canada are also advancing their nuclear initiatives to add more capacity. On top of that, just last week, the United States disclosed an agreement with Saudi Arabia covering the provision of new-new reactors along with nuclear technology, which creates still another avenue for added nuclear demand. All of these cases from just the last several months demonstrate how shrewdly timed our purchases of Paragon and Certrec were, since they positioned us to take advantage of those companies' leading places in the North American market. Now on Panel 5, looking outside North America, fresh data from the World Nuclear Association backs up something we're already witnessing take shape: a once-in-a-generation expansion of nuclear generating capacity across the globe. At present, worldwide nuclear capacity sits at about 400 gigawatts. Under the latest forecasts, that worldwide total will triple by 2050, climbing to nearly 1.5 terawatts — a 45% increase compared with what was projected ten years earlier. And even when you exclude China and Russia from the picture, worldwide capacity still grows by an incredible 2x. Every forecast shown on this panel points the same way: growing need for what Mirion offers, plus a larger installed base that will keep generating recurring demand for many decades ahead. Keep in mind that roughly 80% of the revenue we earn from nuclear power stems from the installed base as it exists today, and that is where a great deal of our recurring and repeat revenue originates. Panel 6 zooms in on the near to medium term. The reactors running right now are delivering foundational growth in demand. Broadly speaking, we observe 3 waves of demand from customers in the installed base nuclear segment. Wave one consists of catch-up capital spending. For many decades, money was tight across the whole operating fleet, so operators ended up with a pileup of maintenance they had put off, along with the replacement components they had no choice but to source. Add the sequence of plant restarts we've already talked about, and what you get is a disproportionately large short-term demand for commercial-grade dedication, reverse engineering and spare parts flowing from PeAks. Life extensions and extended power upgrades make up wave two. Once an operator chooses to go after a life extension, that operator gets far clearer sight lines into continuing to run for another 10 to 20 years. That triggers decisions on upgrades touching instrumentation and controls, plus wider plant ecosystems. Wave three is still taking shape, but it's approaching: digital transformation. A generational handoff is underway in nuclear power, and with it, a wealth of hard-won institutional know-how is walking out the door. The people stepping into those roles grew up with technology, and they're gravitating toward digital tools to preserve and expand that collective expertise. Beyond that, these platforms pack the capability required to fine-tune outage planning and assist plant operators in boosting thermal efficiency. Those dynamics are already translating into a bigger order book, which you can see in Panel 7. As of the second quarter of 2026, backlog stands at over $1.1 billion — roughly 40% higher than the same point last year. Strip out the backlog contributed by the Paragon and Certrec acquisitions, and what remains is legacy backlog, which has climbed 17%. Let's take a closer look at that legacy backlog number, because it helps make my broader point about nuclear power demand picking up. This piece of the backlog has increased quite a bit — it's up 31%, while total legacy Mirion rose 17%. And if you focus just on the legacy Mirion installed base, the figure stands out even more: it's up nearly 40% versus Q2 '25. Panel 8 addresses what investors have been asking about second half revenue visibility; our line of sight to full year revenue expectations remains solid. When you put first half actual results together with backlog we expect to convert into revenue in the second half, roughly 81% of the full year revenue we're projecting is already covered. Crucially, this 81% represents revenue coverage comparable to prior years; that gives us confidence to keep our full year revenue expectations unchanged. In addition, Paragon's PeAks business brings us a new revenue stream that does not show up in backlog. Rather, that revenue gets booked in-quarter. Before handing things to Brian to walk through the quarter, let me take a minute on AI, which Panel 9 covers. This is an area where I now spend a growing share of my time, thinking strategically and steering our business to capture the incredible potential of artificial intelligence. We are putting money into building an early adopter edge by weaving AI into the way we build products, the way we take care of customers, and the way we handle our operations; our AI approach has been structured around 3 separate pillars, each with dedicated resources aimed at speeding up adoption and deployment throughout the company. Accelerating product development is pillar number one. AI is radically reshaping our software development cycles and shortening time to market. To be specific, we're enhancing data analytics, speeding up real-time feedback loops, and refining testing and compliance workflows that would otherwise have required our engineering teams months to carry out by hand. Speeding up our work while keeping our compliance processes rigorous—and actually making them stronger—changes the game entirely. The second pillar consists of efficiencies spread across the whole organization. In that effort, AI is becoming an essential instrument, handling tasks ranging from back-office automation, like reviewing documents, to creating test plans. We remain in the opening stages here, yet the direction we're heading looks promising, and more people internally are starting to embrace it. AI-powered solutions form the third pillar, and that's the one that gets me most enthusiastic; in both segments, we're developing fresh innovations centered on AI. Another key priority for us is building stronger connections between the physical products we sell—think of the instruments installed in nuclear power plants and cancer treatment centers worldwide—and the software and data platforms that generate quantifiable gains in productivity for the people who buy from us. At the AAPM annual meeting held in Vancouver last week, for example, we put a spotlight on Plan AI, our new dosimetry platform, which lets dosimetrists produce patient-specific plans of higher quality at a faster pace. Over in our RTQA business, we also showcased Daily QA 4 Pro, our new offering, which brings dosimetry and imaging checks together into one indexed, imageable solution—cutting down on how often rooms must be entered, shrinking setup time and making execution more consistent from user to user. What matters here is that this fits right into the SunCHECK platform we already have, which means the physics team gets to devote less of its day to logistics and more of it to looking after patients. At this point I'll hand things over to Brian, who will take you through the financials. Brian?
Brian Schopfer
executiveThanks, Tom, and hello everybody on this call. I'll pick up the prepared remarks at Slide 10, where I'll walk through how we performed financially. For the second quarter, total revenue came in at $267 million, which is 20% above the same period a year ago. Organic revenue growth landed at 1%, matching what we had expected and consistent with the outlook we gave in April. Adjusted EBITDA for the second quarter reached $65.3 million, a 27.5% improvement over the prior year. Margin widened by 150 basis points during the quarter, helped by favorable product mix and price in both segments. If you set aside M&A effects and a onetime tariff refund, margin expansion would have exceeded 200 basis points. So far, we have collected roughly $1 million in tariff refunds. Given how the stock has been trading, we deployed about $25 million from our $100 million share repurchase program during the second quarter to take advantage of the price and buy back roughly 1.4 million shares. That pushes our total buybacks this year to about $40 million, leaving $40 million available under the program. Adjusted free cash flow generated in the quarter was $49 million, which reflects stronger adjusted EBITDA, a source of cash from net working capital, and the ongoing benefits of last year's refinancing activities. Finally, as Tom mentioned, second quarter orders were robust, rising 10% compared with last year's second quarter. Nuclear power, once again, was the strongest of our end markets. Slide 11 covers how we keep advancing against our sizable opportunity pipeline. During the second quarter, we captured a number of opportunities, among them the large SMR order at Paragon that we previously disclosed, the second portion of another SMR order, and an additional piece of the radioactive waste handling order in our defense and diversified end market. Though it came a bit later than we anticipated, momentum has remained solid as we moved into July, when over the first 2 weeks we were awarded more than $50 million of large orders, among them a large European installed base order and a U.S. Department of Energy order. Also in July, we were surprised by a cancellation of a Chinese new build order that had originally been booked in 2019. The sites tied to this project have made little progress, and geopolitical tensions that emerged soon after signing stalled these projects. Typically, Chinese new builds move through a much shorter order-to-build cycle. Worth noting: this project does not affect our 2026 guidance and has an immaterial effect on any long-range guides we've provided; altogether, our July awards lift our year-to-date performance to roughly $160 million, with about $280 million of opportunity still open to us. Slide 12 lays out Q2 order book details against Q2 of last year. Before M&A, core orders were up 10%. Total orders, which include a $62 million contribution from Paragon and Certrec, rose 40% in the quarter to $291 million. In Nuclear & Safety, the increase in orders came from strong expansion in the nuclear power end market, roughly 50% excluding M&A, and half of that dollar gain originated with the operating fleet while the rest came from SMRs. Partially offsetting the nuclear power growth were decreases in labs and research as well as defense and diversified. Medical orders in Q2 slipped a bit versus a year ago. Keep in mind the comparison was difficult because we gave priority to Asia orders so tariff exposure would be minimized. Dosimetry orders fell on a hard euro-based order comparison, and nuclear medicine was unchanged. Slide 13 breaks down how Q2 orders performed relative to Q1 of this year. Remember that during the prior quarter we provided guidance of 15% to 20% sequential order growth. Counting the 2 large orders won in early July, net of the Chinese cancellation, orders were up 14%, a touch under that range. Absent the China cancellation, we would have landed at the top end of the range. Before we go through the quarterly financial results, here's an update on the nuclear power end market, found on Slide 14. Nuclear power orders, excluding M&A, rose 50% during the second quarter, driven mainly by both the operating fleet and SMRs; we booked $49 million in SMR orders, which includes the 2 large opportunities described earlier. That's an increase of $42 million compared with last year, showing the ongoing momentum in this space along with Paragon's contribution. On an organic basis, nuclear power revenue overall was flat, as gains in the installed base and SMRs were offset by lower new build revenue. We stay confident that for the full year nuclear power will deliver double-digit organic revenue growth. Now let's move into the quarterly financials, starting on Slide 15. Consolidated second quarter revenue rose 19.7%, reaching $266.8 million. Of that 19.7% growth, about 18% came from acquisitions, primarily Paragon. Organic revenue growth of 1% matched what we guided in April. Second quarter adjusted EBITDA came to $65 million, which is 27.5% above last year's second quarter. Adjusted EBITDA margins widened in both segments, helped by favorable product mix and pricing. Adjusted EPS for the quarter was $0.12 per share. As a reminder, starting in 2026 we are including stock-based compensation in our adjusted EPS calculation. Under a methodology similar to the one adopted for 2026, last year's adjusted EPS would have been $0.09 per share; the appendix contains an adjusted EPS reconciliation slide with the details for your modeling. Moving to the Nuclear & Safety segment on Slide 16. Second quarter revenue was $186 million, an increase of 31%. Organic revenue was 2.3%, matching our April guidance. We remain happy with Paragon's financial performance, which showed 15% revenue growth for the quarter and 27% growth year-to-date, underscoring the stronger demand for their products and services. Since coming under Mirion's ownership, we have kept seeing Paragon's adjusted EBITDA margins widen. We anticipate that trend will persist as we find and capture additional opportunities for integration and synergy. Like we said earlier, revenue growth in the nuclear power end market came in flat, since gains in the installed base and SMRs got offset by reduced new build revenue during the period. New build revenue tends to be lumpy depending on project timing. Adjusted EBITDA rose 35% to $51 million. Margins widened roughly 70 basis points, driven by favorable product mix in Europe, solid cost control throughout the business, and a modest tariff refund here in the U.S. That was partly offset by dilution from the Paragon acquisition. Moving to the Medical segment on Slide 17. First quarter revenue reached $81 million, a decline of 1%. Organic revenue fell 1%, pulled down by the nuclear medicine and dosimetry end markets; that lands below the low single-digit organic growth expectations we disclosed back in April. RTQA revenue keeps growing, fueled by OEM sector performance and our expanding software business. Back in April we noted that during last year's second quarter, we shipped a large quantity of products into Asia before tariffs took effect. Excluding this tariff comp headwind, organic RTQA revenue would have grown mid-single digits; in nuclear medicine, organic revenue dropped because of delayed hardware demand. We do anticipate a pickup in this business during the back half of the year.
Brian Schopfer
executiveOn a positive note, our nuclear medicine software business saw orders increase by a strong double-digit rate during the first half. And finally, the dosimetry services end market recorded negative organic growth as well. That big hardware order from a year ago remains a tough comparison, and it will still be sitting in the back half of the year too. The key point is that, setting that aside, organic revenue for our core dosimetry services rose at a mid-single-digit rate in Q2. For the Medical segment, Q2 adjusted EBITDA came to $31 million, which is 3% above the prior year. Even with revenue lower, margins widened during the quarter, which mirrors price tailwinds, a favorable product mix and software revenue. Tariff refunds in this segment were limited. Moving to Slide 18. I'd like to update you on what we expect from our end markets in Medical, while restating our segment guidance for the full year. For RTQA, we are lifting our outlook to double-digit organic growth for the year, higher than our earlier guide of mid-single-digit plus, which reflects OEM sector dynamics along with continuing strong results from our software offerings. For nuclear medicine, we are bringing our full year guide down to mid-single digits from our earlier double-digit guide, because hardware volume has fallen due to delayed customer demand. As we see it right now, this is a delay rather than a decline in demand. For dosimetry, we now anticipate organic revenue will be negative for the year, lower than our earlier flat guide, because of reduced hardware revenue. Keep in mind that we are also up against the tough comparison from hardware sales in 2025. We still expect total service revenue growth to be low single digits plus, consistent with historical guidance; these puts and takes mostly cancel out, and our full year Medical segment guidance stays the same. Now to adjusted free cash flow on Slide 19. We produced $49 million of adjusted free cash flow in Q2, bringing the first half of 2026 to $60 million of adjusted free cash flow. That gain marks our strongest first half adjusted free cash flow since we became public, and it comes from solid control of our net working capital along with continuing metric improvements, lower cash taxes and enhancements to our capital structure. Now to Slide 20. Our full year 2026 guidance has not changed since April. Given what we covered earlier regarding our backlog coverage, Slide 21 indicates that we expect an uptick during the second half of the year. On organic revenue growth, the first half landed at 2%, weighed down by tough comparables from last year's tariff-related pull-forward on the medical side and a challenging Q1 '25 nuclear power comp; we expect organic revenue to rise meaningfully in the back half, landing between 7.5% and 11.2%, led by the nuclear power end market in Nuclear & Safety and the RTQA end market in Medical. On margins, first half adjusted EBITDA margins were 22.8%, a drop of 23 basis points year-over-year due to dilutive M&A and mix impacts from Q1 '26. In line with typical seasonal patterns, we anticipate margin acceleration during the back half of the year, with rates landing somewhere around 27% to 29%, which is roughly 150 basis points higher than a year ago as operating leverage takes effect. For the second half, adjusted free cash flow is projected to come in between $95 million and $115 million, and given that Q1 was our softest quarter, Q4 is set to be our biggest quarter for generating cash. Right now, we're leaning toward the upper end of that range. Taken together, faster organic growth and widening margins, along with a solid backlog, are the reasons we stay confident in our full year guidance even after a slower first half. Prior to opening the line for Q&A, let's take a moment to go over the third quarter guidance found on Slide 22. We expect consolidated third quarter organic revenue growth in the high single digits. Nuclear & Safety should come in at mid-single digits, and for Medical we're anticipating high single-digit growth. Compared with last year, consolidated adjusted EBITDA margins should widen. For the Nuclear & Safety segment, adjusted EBITDA margins are set to contract, which mirrors the dilution effects from Paragon, a comparison against a reduction in incentive compensation from 2025, and the mix shift effect tied to anticipated higher new build revenue during the quarter. As a reminder, new build projects usually carry a somewhat lower margin than the installed base. For the Medical segment, adjusted EBITDA margins should widen thanks to operating leverage from rising revenue growth relative to the first half of the year. With that said, we're glad to take your questions.
James West
analystSo I'm curious about what you all discussed regarding that big pipeline of opportunities. You've talked about a substantial amount of potential being out there. As you mentioned in your slide deck and in your remarks this year, much of it remains available, and that also holds as we head into '27. And I'm wondering if you could give us some sense of how much of that potential is, I suppose, yours to lose, so to speak, or follow-on contracts. I mean, how much of it is definitely headed to Mirion? How much is essentially up for grabs by others? I'd like to hear your perspective on how much of that we should expect to carry over into Mirion.
Tom Logan
executiveSure, James — let me start us off, and then Brian can add some further detail. From our standpoint, we believe we're positioned to come out ahead across all of these areas. To explain how we sort through these, and to give you a fuller picture: we're looking at deals worth more than $10 million, and ones where we figure our chances of coming out on top are probably better than 50% — in other words, where we believe we've earned the right to compete and win. Looking back at the opportunities that actually closed during the most recent quarter, my sense is we came away with every single one. As far as I can tell, nothing that changed hands during that stretch went to someone else. So we stay confident in our capacity to keep up that kind of record. From where we sit, the main exposure is usually schedule slippage — projects can drift later depending on what kind of work they involve, which industry they belong to, and so on. That said, I'd point out that this pipeline keeps refilling and growing as a whole. So taken together, we're quite optimistic.
James West
analystAll right. Okay, that's completely clear. And now perhaps a somewhat separate question. Earlier this year, while we were on the road together, we discussed the M&A landscape, and you stated very plainly that you had a pipeline, and that it was robust; and I'm wondering — just interested to know whether anything has shifted on that front? Or ought we to anticipate announcements? What's the situation with the target list?
Tom Logan
executiveYes. I'd describe our M&A pipeline as continuing to be strong. The market holds plenty of genuinely compelling assets that, in our view, fit very well strategically alongside our business model. And this — M&A, to be explicit, has always formed a key element of our strategy; we've completed around 20 deals across the past 10 years. And what we expect is that we will keep on being active in this area.
Joe Ritchie
analystYou all gave us plenty of useful detail regarding how confident you feel about the guidance as we move through the remainder of the year. Perhaps just this — when I look only at the Nuclear & Safety segment, my read of the implied guidance suggests something like at least mid-teens organic growth during the fourth quarter. What I'd like to understand is how much of that already sits in backlog? Then maybe share a bit more detail about that ramp from here through the end of the year.
Brian Schopfer
executiveYeah. I believe you're — I mean, this is exactly why we provided a fairly implicit Q3 guide, since you can now work it down to the fourth quarter. Your math looks correct to me. I think we laid the visibility out there for the remainder of the year, and we gave it in totality. So 81%. So we sit essentially right where we sat at this same point in each of the other quarters after Q2. And as a reminder, looking backward, we're discussing where we truly ended up on revenue versus what we expected would come from backlog; so the comparison lines up quite evenly; so look, we issued the guide. We feel really good about our position. We have solid visibility into the back end of the year. There's obviously work still to do on the execution front, and we still need to win orders. I think the orders we booked in early July also assist us along the way; so we keep feeling good about where we stand, Joe. And we realize that's — a mid-teens guide for the fourth quarter is significant; but I'd also say the comps for us more broadly during the back half of the year are smaller than those we saw in the first half of the year, and I think that provides us a tailwind there as well.
Joe Ritchie
analystYes, that's useful, Brian. Perhaps a wider question for Tom. Speaking of that China debooking, I realize it amounted to only $18 million, but those contracts dated all the way back to 2019. Could you maybe discuss how you folks view the backlog you hold today, whether any potential risk exists from some of these legacy contracts, and why debook that particular contract now, this quarter?
Tom Logan
executiveYes. Joe, we constantly review our backlog, and as you know, debooking events have been extremely uncommon throughout our history; these are highly unusual occurrences, usually connected to some larger problem. Soon after our IPO, we debooked a Finnish order linked to the Ukraine conflict. A couple of years afterward, we had a debooking in Turkey tied to what I'd describe as a localized contractual dispute. And then this latest one arrived, frankly, somewhat unexpectedly. To be clear, looking at the contractual provisions, no exit provision exists, and clearly we'll hold extensive discussions and negotiations around this matter. That said, this contract was basically supported by a project progressing very slowly; it's a contract booked many years ago and frankly has been affected by some altered trading dynamics, particularly between the U.S. and China. So beyond that, regarding our backlog quality, we believe it remains very high; we don't perceive any elevated risk. We don't view this as a trigger event of some sort where others trail behind us, and once more we remain confident in the dry powder we hold there overall. Another point I'd mention, Joe — you didn't ask about this, but worth noting. Considering the Chinese market as a whole, understand that currently, if you examine our installed base position, we hold a meaningful position across 50 of 60 operating Chinese reactors; and that experiential track record frankly even precedes Mirion. It stretches back roughly 30 years. We've been a long-standing fixture in this market. Yet we've also been very clear that over time, across those decades, we've witnessed declining wallet share overall in the Chinese market, driven by factors familiar across every industry. But importantly, as we stand today, we continue to see what I'd characterize as a robust and predictable spare parts market there, again acknowledging that position across 50 reactors in China. But looking back across the last 5 years, it's averaged roughly $8 million annually, and we're confident that will persist. Also, if we examine what’s happening with new construction, there are 2 main channels, plus what I would call a third, less significant channel in China’s new-build work. The main emphasis today is on a domestic reactor design known as the Hualong reactor, and basically we’re shut out of it. We have nothing in it. What’s planned for the Hualong is that it’s a reactor that is 100% made in China and locally produced. Still, to be clear, export chances remain in China via derivatives of the Westinghouse AP1000 technology, the Framatome EPR technology and the Rosatom VVER opportunity. And we expect that we will keep having BATs there, and that will keep going across our planning horizon. One last point I’d make on China is that at present we are quite active in 3 advanced reactor applications in China. China is very active in the SMR market as a whole and is doing some genuinely interesting work with advanced reactor technology, and that remains an opportunity for us as a whole. So this debooking was disappointing. There will be more to the story that unfolds over the next few months. But we don’t see it as signaling some wider set of problems for us.
Quinn Fredrickson
analystTo add to what was asked about SMRs a moment ago — it's obvious you've got real momentum right now, given those sizable orders, plus the expectation that this goes from 2% of revenue up to 3% across this year. My understanding is that 2030 has been talked about as the point when SMRs see broader commercial deployment. Still, judging by that order momentum and the visibility in front of you today, ought we to consider that the share of revenue you get from SMRs will scale even more in '27?
Tom Logan
executiveQuinn, here's how I'd put it: the theme that keeps recurring is that although we've historically been extremely careful about voicing confidence in the SMR timeline as a whole, reality keeps shifting to the left. Opportunity flow in this sector is coming at us stronger and stronger. Where we sit is fairly distinctive, given how broad our capabilities are that matter to these players as a group. So our take is that the growth dynamic — and I won't attach specifics to guidance here — our take is that the growth opportunity in front of us is substantial, and that momentum keeps accumulating. That leaves us increasingly bullish about the sector. We're increasingly bullish about where we sit, about our right to win, so to speak. And though I won't necessarily name them all at this point, my expectation is that this keeps growing at a pace exceeding our overall organic growth rate over the rational planning horizon.
Quinn Fredrickson
analystThen moving to my follow-up question about Nuclear Medicine. Could you explain a bit more about what led to lower hardware volume and softer demand in the quarter, and then break down why you feel confident about that second-half improvement you referenced?
Brian Schopfer
executiveSure. My sense is that things simply paused somewhat during the first half. We're looking for additional momentum in the drug pipeline, I'd say. The team remains quite bullish regarding the second half, based on what we started seeing as June wrapped up. Our software business within Nuclear Medicine posted really robust order growth across the first six months of the year. I believe I referenced double digits, and it was solidly in double digits, for what that's worth. We've devoted considerable time at that factory. As you may recall, an ERP implementation took place there. We've also merged a few factories at that location. That facility is definitely performing better now than previously, so lead times have dropped significantly. As a result, our capacity to book and ship within that business across a quarter — across two quarters has gone up substantially. So I'd say all of those factors are influencing things right now. And this is something we keep monitoring, something we remain hopeful about as we move through the latter portion of the year and into '27.
Andy Kaplowitz
analystTom, I'd like to pose what Joe asked, just framed a bit differently. Orders for nuclear power climbed 47% excluding M&A. Yet, as you're aware, nuclear power revenue remained roughly flat during Q2. So why has that gap between the two persisted for such a long stretch? And when I consider what's picking up in Q3, I recall you mentioning that you're beginning to lap far simpler comps in new nuclear; so is it really that straightforward, or could there be a bigger contribution from SMR plus installed base projects also ramping, and have you noticed any turning point yet in July?
Brian Schopfer
executiveYes. Well, I mean, look, to reach the back end figures, I mean, I believe we anticipate a step-up across all 3 components of the nuclear power business; SMR, new build and MPP; and just to remind everyone, I mean MPP accounts for 80% of nuclear power revenue for us. Clearly, to reach the back end of the numbers, that business needs to perform; and I think I made a few remarks in my script, Andy, that nuclear power growth was quite strong and it was split evenly on a dollars basis between the installed base and the SMR space, and you can see a lot of the SMR activity arrived through the large orders; so I think that keeps giving us confidence that this business is positioned to deliver in the back half of the year. And once more, like Joe asked specifically about Q4, but more broadly, we're sitting at a coverage base that at the midpoint of our guide matches where we sat each year essentially over the last couple of years. I would say if you added the peak's revenue, that hands you another incremental percentage point of coverage, for what it's worth, on the back end plus the wins we saw in early July although it won't be a lot of revenue that kind of comes through the P&L, that keeps strengthening our coverage dynamics. So hopefully, that's a bit more color that kind of helps give you confidence.
Andy Kaplowitz
analystThat's quite useful. And now, Tom, perhaps at a high level. My sense is that during the past two quarters or so, the market has been somewhat more fearful that the spread of what we might term short cycle power supply could in some way affect the nuclear cycle. You presumably speak with many customers, so what are you hearing? Do customers feel any concern at all about this? In your view, how confident are your customers that once they reach the end of these longer cycle nuclear projects, there will be sufficient demand available for them? Just your perspective.
Tom Logan
executiveYes. From a contextual standpoint, Andy, I believe there's a wider perception that might be somewhat mistaken that we are essentially tied to the data center build-out cycle. And although new data centers are plainly the largest source of additional energy demand across both regulated and deregulated markets as a whole, we regard it as somewhat more binary. What I mean by that is, again, consider a historical point, 5 years back, or more specifically, 10 years back, when nuclear power plant operators were genuinely struggling economically and consequently were in severe capital rationing modes, truly attempting to cut down on OpEx, and so forth. Today, the situation looks vastly different. Even if there's a sharp downturn in the pace of building data centers, they've essentially arrived at an either-or decision: they want to extend how long their existing asset base keeps working by two more decades, and for us that's the primary catalyst. As soon as that decision gets made, it generates a deliberate requirement to put money into a wide range of systems and subsystems, many of which turn over on a ten-year cycle, while a few actually run through a full twenty years. To start, when you look at the nuclear sector, the broad anxiety around both supply and demand factors doesn't hit us as hard, I'd say, mainly because the key choices are wanting to keep my plant running longer and then wanting to actually run that capacity. Remember, the worldwide installed base generates 80% of what we earn. That's the core idea, the core thing to grasp, when someone evaluates our business. On the edges, obviously, additional data centers translate into added generating capacity, and the small modular reactor segment probably gains the most advantage from all of that. From our perspective, though, we see that as potential we haven't counted on—something that gives us options, and it matters far less to us than how that installed base grows over time.
Chris Moore
analystCan you give some color on the margin side? Obviously, Paragon — that deal continues to look very attractive. What I'm wondering is whether it makes hitting that 30% EBITDA goal for '28 a bit harder, just to frame it. The '25 margin is 24.6%. This year's guidance midpoint, if I'm right, is 25.6%, which is 100 basis points higher. For next year, consensus sits at 27.1%, so about 150 basis points of improvement. That means either we need a 300 basis point jump between '27 and '28, or the '27 numbers are too conservative. So really, my question is whether I've got that math right. How should we think about the factors behind the EBITDA margin growing by a larger amount in 2027 than in 2026, and possibly expanding further in 2028?
Tom Logan
executiveSure, Chris. Let me begin at a broad level and go through the key components that get us to that roughly 4.5 points of improvement, assuming we land at the midpoint of guidance for year-end 2026 EBITDA margins, around 25.5%. As we've talked about many times, the largest piece for us is operating leverage. Because of how our fixed and variable costs are structured, we have a very strong degree of operating leverage. So at the margin, what that translates to is contribution margins coming in higher than gross margins. And as long as we stay disciplined about factory overhead and SG&A growth, we'll capture a bigger share of that fall-through. Looking ahead, we'd expect at least half of that go get to come purely from operating leverage as the top line keeps growing. Procurement is our second big piece; over the past 2 years, we've achieved substantial improvements in procurement efficiency and the related cost dynamics. There's still a healthy pipeline of in-stream projects ahead of us, and those really speak to a multiyear effort to push our supply chain toward a more optimized state. Based on what we can currently see and what sits in that pipeline, our belief is that this delivers an additional 1 to 2 points of margin across this timeframe. Then there's the last component, which is really the self-help work that goes past procurement. That means deploying our business system, which AI is now helping us do even more with on the internal productivity side. This covers a lot of ground — making our conversion efficiency better, and making sales and operational planning better. We keep refining how our plants are laid out, since overall we're sitting on more capacity than demand requires. On top of that, we're streamlining every administrative SG&A process and similar areas. Along those lines — if you could see how we rank our priorities, you'd notice we're confident a sizable backlog of chances exists. One point worth mentioning alongside all of that: this quarter we earmarked funds for a restructuring of the organization that's happening right now. Basically, what's driving that is a chance we see in the near term to keep evolving and making our organization more efficient — looking at spending across layers, plus other factors — and that should deliver more of a near-term lift on the margin radar as we look toward '27 overall. So to be clear, we're still committed to a 30-point target — it's a bold one. It's one we're highly driven to hit. And even with the dilutive effects from certain M&A deals we've completed, we're going in with our eyes open.
Chris Moore
analystUnderstood, that's really useful. Perhaps a brief follow-up regarding what you discussed at length on the AI front. I'm just curious whether there's a sizable amount of spending currently going toward AI, or whether a lot more is expected before you reach where you're aiming?
Tom Logan
executiveAs things stand for us, while we keep developing our AI capabilities across the organization and in this area, it involves a mix of data infrastructure plus expanding our engineering capabilities. And beyond that, there's token expenditure company-wide. At present our spending rate — looking at it from a cash perspective, with the majority being OpEx and a portion being CapEx — sits at roughly $5 million, and that figure is increasing; and clearly it's something we keep in mind when considering margin dynamics as a whole. No, it isn't an outrageous figure, yet it is a material one.
Jeff Grampp
analystRegarding the pipeline for '27 — that big set of opportunities you mentioned on the slide as building or growing — I'm curious about how things look now compared with the same point last year, given that we have a sense of how the '26 pipeline turned out. Any observations, comparisons, or themes worth flagging at this stage, recognizing that it's still somewhat early to say anything with real certainty?
Tom Logan
executiveYes. Jeff, thematically speaking, the largest difference between now and twelve months ago, I'd say, is the SMR opportunity set, which, as I mentioned, is generating quite a lot of tangible engagement on our end. And the set of opportunities tied to new build activity in the SMR space keeps growing. Beyond that, though, we're seeing meaningful gigawatt scale opportunities, plus a variety of other opportunities connected to federal government work and global analogs for it, which is broadly consistent with what was visible a year ago. So the largest difference would be on the new build side, and most specifically in the SMR area.
Jeff Grampp
analystGreat. Those specifics are helpful. My follow-up is a bit more near-term, about what you said regarding Q3. For Nuclear & Safety, I believe you anticipated growth in the mid-single-digit range, and inside that, power in particular at double digits; so that suggests a few of the other contributors are somewhat slower or lower. Does that apply only to Q3, or could you speak to those dynamics a little regarding the other revenue buildups in the Nuclear & Safety segment?
Brian Schopfer
executiveYes. I mean, I think your math is correct. I think on the Nuclear & Safety side, from an end market perspective, we haven't shifted much of our full year guidance. So we still believe labs and — at least that's how we continue to model it, and we'll see how it turns out. For the year, labs and research will be flat. The diversified business will be roughly mid-single digits-ish. And then the nuclear power business, as we said, is double digits. Obviously, the math mentioned earlier in the Q&A about the fourth quarter, roughly a teens number, suggests that Nuclear & Safety is a large portion of that. At this time, I don't really have anything else to add beyond that.
Tomo Sano
analystRegarding July, net bookings came to $37 million. What drove that the most — can you provide additional detail? Also, is this something we ought to view as a run rate, or is it tied to timing? It would be helpful if you could offer further insight regarding the second half.
Brian Schopfer
executiveSure. To make sure it's clear, the $37 million net figure consists only of the 2 sizable orders we secured during the first 2 weeks of July, along with the Chinese cancellation that we've already discussed. Nothing broader is captured in that number — nothing from orders below the $10 million scale, or really from the book-to-bill business.
Tomo Sano
analystBrian, would you be able to discuss a few of the possibilities and the momentum heading into your back half when it comes to the large opportunity pipeline? That would be great.
Brian Schopfer
executiveSure. So, over on the right-hand portion of that slide, you're able to see it. There are still, for the most part, roughly 12 opportunities sitting in the queue, and 8 of those we'd put in the new build category, meaning both utility scale and SMR; as you can see noted, this is something we haven't done before, but that accounts for approximately 15 reactors within it. So clearly the ratio isn't 1:1. So once more, like Tom said, on each of those we're comfortable with our right to win. As for how the timing shakes out between Q3 and Q4, well, I got burned on exactly that during the second quarter; so pinning it down again in the third quarter isn't something I'm going to attempt. Still, our belief holds that all of these opportunities ought to and potentially could trade this year, and we'll find out how that unfolds. Naturally, within the installed base we keep seeing a handful of things of size. That said, I'd say on a size basis there are fewer $10 million-plus projects sitting in the installed base, and then the DOE, I'd describe as sort of that final bucket; and out of the DOE we keep seeing really solid activity on the pipeline side, and whether that lands with us here in '26 or perhaps '27 is something we're monitoring. Clearly, we're also keeping a close eye on the government shutdown dynamics in Washington. So plenty is going on. Even so, our belief holds that there's a great deal out there for us when it comes to the larger scale stuff. And that flow of business keeps carrying good momentum.
Tomo Sano
analystAnd a single brief follow-up regarding how we're deploying capital. Given that you're producing more robust free cash flow while aiming for reduced leverage, what's your thinking on capital allocation over the medium term? Tom, I believe you brought up investing in AI along with certain M&A possibilities. Then Brian, you discussed repurchasing shares. We'd welcome any fresh information.
Tom Logan
executiveRight. Tomo, assuming we pursued zero M&A through the rest of this year, based on our operating plans and the plans we have for capital spending, leverage would finish the year at roughly 2.5x, around that level. Once more, we have a reasonable pipeline inside that; these are typically on the smaller side as deals go. Thus, when we consider capital allocation broadly, M&A stands as our top strategic priority, yet leverage will without question decline on a net basis as the year progresses, and how much M&A affects that remains to be determined.
Tom Logan
executiveOkay, everyone, thanks for being here and for listening. Once again, we’re glad to share what happened in Q2. We’re clearly enthusiastic about the backing we’ve got for Q3 and Q4, and we can’t wait to catch up again in 3 months, when we’ll refresh our guidance at that moment. Thanks for your time. Thank you.
Operator
operatorThat brings today's call to an end. At this point, you're free to hang up. We appreciate you joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mirion Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Mirion Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Mirion Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.